Base Editing in DMD
Innovation Creates Hope
Recent News
View AllGenAssist Ltd will Present Three Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
GenAssist announced that three posters will be released at the at the 32nd ESGCT
Read MoreSafety Update of Global First DMD Base Editing Therapy—GEN6050X
GenAssist announced that the third patient enrolled in the IIT study of GEN6050X at Peking Union Medical College Hospital has successfully completed the 30-day follow-up with no serious adverse events reported
Read MoreGenAssist Ltd Receives U.S. FDA Rare Pediatric Disease Designation (RPDD) for GEN6050X in Treating Duchenne Muscular Dystrophy
GenAssist announced that the United States (U.S.) Food and Drug Administration (FDA) is P02506240
Read MoreOur Value
Our Vision: To Benefit Human Health through Innovation.
Our Mission: Transforming Cutting-edge Science into Life-changing Medicine.
Our Story
Founded in July 2020, GenAssist Ltd. (GenAssist) is a pioneering gene editing drug company. The operation entity of GenAssist is located in Suzhou, China, with two subsidiaries in Shanghai (China) and Boston (US). GenAssist owns the global rights of Targeted AID-mediated Mutagenesis cytosine base editor technology. The company is dedicated to developing base editing drugs against life-threatening diseases.
Our Pipeline
Utilizing TAM base editing technology, our product can precisely modify target DNA, inducing exon skipping, activating alternative splice sites, and editing splicing regulatory elements, with the ultimate goal of curing multiple diseases.
Our Platform
Our AAV Platform is highly versatile and modular, offering broad potential across therapeutic areas. We are already developing potential treatments spanning discovery to clinical-stage across multiple devastating diseases, and this is just the beginning.